ABVX
AbivaxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful Phase 2 readouts and a strategic licensing deal would de-risk the pipeline and re-rate the stock toward analyst highs [#SERP-1].
Posture
Constructive
Lead driver
Sentiment
What changed
3 setup hits (3d) with net neutral as of 2026-06-02.
What can break
Binary clinical readout risk (trial failure or inconclusive efficacy)
Momentum
69
Value
41
Sentiment
100
Setup hits (3d)
3 · Net Neutral
AI TargetsBase $130.14 · Bull $176.00 · Bear $101.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $151.34
Why
Momentum69 · Δ7d -3.4
Value41 · Δ7d +0.1
Sentiment100 · Δ7d -3.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
69
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
+4.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
+1.7
Why this grade
Composite grade A. Momentum 68.8 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$10.37B
Beta
1.48
Shares Out
63.47M
P/E (TTM) · Derived
-49.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-70.18
Rev YoY
-
EPS YoY
-23.8%
Gross Margin
-
Op Margin
-
Net Debt
-$60.13M
Current Ratio
0.77
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology